PubMed Health⌕ Search

Biomedical subjects

L Perrin

Publications and source records attributed to L Perrin.

151 records · Page 9Linked to original sources
PubMedDate not supplied

Primary fallopian tube carcinoma: the Queensland experience.

The purpose of this study was to review the experience with fallopian tube carcinoma in Queensland and to compare it with previously published data. Thirty-six patients with primary fallopian tube carcinoma treated at the Queensland Gynaecological Cancer Center from 1988 to 1999 were reviewed in a retrospective clinicopathologic study. All patients had primary surgery and 31/36 received chemotherapy postoperatively. Abnormal vaginal bleeding (15/36) and abdominal pain (14/36) were the most common presenting symptoms at the time of diagnosis. Median follow-up was 70.3 months and the median overall survival was 68.1 months. Surgical stage I disease (P = 0.02) and the absence of residual tumor after operation (P = 0.03) were the only factors associated with improved survival. Twenty of the 36 patients (55%) presented with stage I disease and survival was 62.7% at 5 years. No patient with postoperative residual tumor survived. The majority of the patients with fallopian tube carcinoma present with stage I disease at diagnosis, but their survival probability is low compared with that of other early stage gynecological malignancies. If primary surgical debulking cannot achieve macroscopic tumor clearence, the chance of survival is extremely low.

Abdominal Pain↗
PubMedDate not supplied

Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study.

PURPOSE: By protecting and stimulating HIV-specific CD4 cell responses, treatment of primary HIV infection (PHI) with potent quadruple HAART could lead to prolonged suppression of HIV replication after cessation of antiretroviral therapy. The QUEST trial investigates this hypothesis and aims to determine whether addition of a therapeutic vaccine to HAART increases the likelihood of prolonged viral suppression compared to HAART alone. METHOD: 148 patients with PHI were recruited. Participants were treated with open-label HAART for at least 76 weeks. Participants with sustained viremia <50 copies/mL were randomized to one of three 5-month, double-blinded study treatment groups: HAART alone, HAART + ALVAC-HIV (vCP1452), or HAART + ALVAC-HIV (vCP1452) + Remune. After a further month of HAART alone, all treatment was stopped where plasma HIV-1 RNA remained at <50 copies/mL. Intensive virologic and immunologic monitoring during a 24-week observation period followed treatment interruption. Patients who met treatment reintroduction criteria were offered HAART rescue.

AIDS Vaccines↗
PubMedDate not supplied

Acute HIV infection.

In this short review, clinical manifestations associated with primary HIV infection (PHI) and their impact on progression to AIDS will be described. High levels of viral replication of viruses with a restricted heterogeneity and decreased CD4/CD8 cell ratio are hallmarks of PHI. Within weeks to months following PHI, a marked decrease in viremia and an increase of CD4 cells which stabilise at levels below normal values occur. Early decrease of viremia to low levels, low proviral levels, stabilisation of CD4 cells to values close to the normal range postpone the development of AIDS. Tentative goal of early antiviral therapy in PHI might be, by decreasing viral load, to restore CD4 cell levels to normal value and to transform the majority of PHI patients into long-term non-progressors. Selection of therapeutic regimens, duration of antiviral treatment and validation of appropriate virological and immunological markers are the key issues in the context of PHI treatment. These issues and the results of therapeutic interventions with mono and bitherapy in PHI as well as combined drug regimens for future studies are presented and discussed.

Acquired Immunodeficiency Syndrome↗